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Early studies of narcolepsy after AS03-adjuvanted pandemic A/H1N12009 vaccine (Pan-
demrix) could not define the duration of elevated risk post-vaccination nor the risk in children
aged under 5 years who may not present until much older.
Methods/Findings
Clinical information and sleep test results, extracted from hospital notes at 3 large pediatric
sleep centers in England between September 2017 and June 2018 for narcolepsy cases
aged 4–19 years with symptom onset since January 2009, were reviewed by an expert
panel to confirm the diagnosis. Vaccination histories were independently obtained from gen-
eral practitioners (GPs). The odds of vaccination in narcolepsy cases compared with the
age-matched English population was calculated after adjustment for clinical conditions that
were indications for vaccination.
GP questionnaires were returned for 242 of the 244 children with confirmed narcolepsy.
Of these 5 were under 5 years, 118 were 5–11 years, and 119 were 12–19 years old at diag-
nosis; 39 were vaccinated with Pandemrix before onset. The odds ratio (OR) for onset at
any time after vaccination was 1.94 (95% confidence interval [CI] 1.30–2.89), The elevated
risk period was restricted to onsets within 12 months of vaccination (OR 6.65 [3.44–12.85])
and was highest within the first 6 months. After one year, ORs were not significantly different
from 1 up to 8 years after vaccination. The ORs were similar in under five-year-olds and
older ages. The estimated attributable risk was 1 in 34,500 doses. Our study is limited by
including cases from only 3 sleep centers, who may differ from cases diagnosed in nonpar-
ticipating centers, and by imprecision in defining the centers’ catchment population. The
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potential for biased recall of onset shortly after vaccination in cases aware of the association
cannot be excluded.
Conclusions
In this study, we found that vaccine-attributable cases have onset of narcolepsy within 12
months of Pandemrix vaccination. The attributable risk is higher than previously estimated
in England because of identification of vaccine-attributable cases with late diagnoses.
Absence of a compensatory drop in risk 1–8 years after vaccination suggests that Pandem-
rix does not trigger onsets in those in whom narcolepsy would have occurred later.
Author summary
Why was this study done?
• The AS03-adjuvanted H1N1 pandemic vaccine Pandemrix was shown to be associated
with an excess of cases of narcolepsy, but studies could not determine for how long after
vaccination the risk was elevated nor whether there was a later compensatory reduction.
• These early studies were unable to assess the risk in children vaccinated under 5 years of
age because of the long diagnostic delays in this age group.
• There were also concerns that the elevated risk shown in these early studies may have
resulted from ascertainment bias due to the earlier presentation and diagnosis in cases
known to be vaccinated. Addressing these questions requires studies that have a long
follow-up interval after vaccination.
What did the researchers do and find?
• Records at 3 large pediatric sleep centers in England were searched to find cases of nar-
colepsy aged 4–19 years with symptom onset since January 2009. Independently Pan-
demrix vaccination histories of these cases were obtained. The proportion of cases
vaccinated before onset were compared with that in the age-matched population at the
time of symptom onset in each case.
• A 7-fold elevated risk of onset of narcolepsy after Pandemrix was found, which was con-
fined to the first year after vaccination, with the highest risk within 6 months. No evi-
dence of a compensatory drop in risk to below one between 1 and 8 years after
vaccination was seen.
• Vaccine-associated risk was similar in children vaccinated under 5 years or at an older
age.
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What do these findings mean?
• The long follow-up interval makes it unlikely that bias because of earlier diagnosis in
vaccinated cases generated the elevated risk reported after Pandemrix and provides
strong confirmatory evidence of a causal association.
• The new information on the period of elevated risk after Pandemrix will help clinicians
decide on causality in individual narcolepsy cases with a history of vaccination.
• The lack of a drop in risk below baseline after a year indicates that Pandemrix was
unlikely to have accelerated the onset in those who were destined to develop narcolepsy
later.
Introduction
In August 2010, concerns were raised in Finland and Sweden about a possible association
between narcolepsy and the AS03-adjuvanted H1N1 pandemic vaccine Pandemrix following
reports of an excess of cases in recently vaccinated children [1,2]. A subsequent cohort study
in Finland reported a 13-fold increased risk of narcolepsy following Pandemrix in children
aged 4 to 19 years, almost of whom had onset within 6 months [3].
Pandemrix was the predominant H1N1 vaccine used in Europe, with over 30 million indi-
viduals vaccinated. In the UK, Pandemrix was used from October 2009 for individuals consid-
ered at high risk followed by children under 5 years of age from December onwards. It was
used again in the UK in the 2010/11 season because of a shortage of seasonal influenza vaccine.
Over 5 million UK subjects received Pandemrix [4].
To investigate the association reported from Finland, the Health Protection Agency (now
Public Health England) performed a study in 2011 in sleep centers in England. This identified
a 14-fold increased risk in those vaccinated with Pandemrix aged under 19 years with an esti-
mated attributable risk of 1.9 per 100,000 doses [5]. Subsequently, Public Health England
investigated the association in adults and found a 9-fold increased risk with an attributable
risk of 0.6 per 100,000 doses [6]. Increased risks in children and adults have also been reported
in other European countries where Pandemrix was used, but no association has been seen
with other pandemic or seasonal vaccines [7]. Despite the consistency of the findings, it has
been suggested that the elevated risk estimates reported in these studies are biased due to more
rapid diagnosis in cases known to have been vaccinated [8,9].
Narcolepsy cases usually have a long period between symptom onset and diagnosis. Because
the studies reported to date had relatively short follow-up periods, usually less than 2 years,
cases with an extended period between symptom onset and diagnosis or with a long onset
interval after vaccination would not have been identified. In addition, narcolepsy is rarely
diagnosed under the age of 5 years, so any risk in children vaccinated at an early age would not
have been assessed. We therefore conducted a further pediatric study in England 8 years after
Pandemrix was first used to re-evaluate the risk when including cases with a delayed diagnosis,
to investigate the postvaccination period in which the risk is elevated and to assess the risk in
those too young to be diagnosed at the time of the previous study. In addition, long-term risk
estimates were used to assess whether the vaccine may have triggered early onset in cases that
would otherwise have occurred later.
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Methods
The study protocol and preplanned analyses are provided in S1 Text. The intention was to
include 5 study sites, but as sufficient cases had been recruited to meet the sample size require-
ments at the first 3 centers, the remaining 2 sites were not included. The STROBE check list
for observational studies is provided in S1 STROBE checklist.
Case ascertainment and validation
Hospital episode statistics (HES) in England [10] with an ICD10 code G47.4 for narcolepsy
were used to identify the 3 major pediatric centers for narcolepsy diagnoses in England. The 3
centers, all which participated in the 2011 study, were visited between September 2017 and
June 2018. The age distribution and the sex ratio of HES cases at the 3 centers were similar to
that at other centers not visited (S1 Fig).
Cases aged 19 years or under at the time of diagnosis were identified using local databases,
multiple sleep latency test (MSLT) case lists, electronic patient records, and a clinic letters
search for the keyword narco. The case lists from the local search, HES, and the previous study
were merged and de-duplicated using NHS number or surname and date of birth. These
potential cases were then reviewed using electronic medical records to establish symptom
onset date, clinical history, and sleep study results with any missing information supplemented
by review of paper case notes (Fig 1).
The anonymized clinical information from each center was then evaluated by a review
panel of sleep medicine clinicians (authors PG, TQ, JShn, ZZ) prior to ascertainment of vacci-
nation status. Cases with a clear history of excessive daytime sleepiness (EDS) and cataplexy
with a positive MSLT or low levels of hypocretin in cerebrospinal fluid (CSF) were not sent to
the panel for review. The panel used the International Classification of Sleep Disorders Third
Edition (ICSD-3) [11] and categorized each case as Type 1 (cataplexy and/or low hypocretin
levels), Type 2 (no cataplexy, hypocretin normal or not measured), possible, or exclude. A con-
sensus of 3 of the 4 panel members was required to assign a final diagnosis.
A questionnaire was sent to general practitioners (GPs) for patients categorized as Type1 or
Type 2 narcolepsy requesting information on EDS or cataplexy symptoms, date these symp-
toms first occurred, and date of first consultation about these symptoms. Pandemic influenza
vaccine dates were also requested together with batch/lot number and whether the patient was
in an influenza vaccine eligibility risk group in 2009.
Index dates
The date of first symptoms, date of first healthcare contact, and date of diagnosis were determined
from the medical records at the sleep center or from the GP questionnaire. The date of first symp-
tom was defined as the earliest date of EDS, or cataplexy if that was the presenting symptom, as
reported by the GP or mentioned in the hospital notes. Date of diagnosis was the date of the sleep
test or if not done the date of the first letter from the sleep center confirming a narcolepsy diagno-
sis. A best first symptom date and earliest and latest possible first symptom date were assigned
using all the information on the timing of the onset before the vaccine status was sought. The best
estimated date was used for the main analysis and the earliest and latest dates as a sensitivity anal-
ysis. In general, the month midpoint (15th) was used unless a very specific date was given.
Statistical analysis
The association between Pandemrix and narcolepsy was assessed using the case-coverage
method [5,6,12], which compares the proportion of cases vaccinated with the proportion
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vaccinated in the population from which the cases arose (i.e., vaccine coverage in that popula-
tion). With this method, the population for which coverage is obtained will contain both cases
and noncases, but for rare conditions such as narcolepsy, this will approximate to the coverage
in noncases. Where coverage is rapidly changing over time and varies by age and clinical risk
group, as with the roll out of Pandemrix, the coverage population needs to be matched by these
variables. To obtain for each case the age-matched population coverage in England according to
risk group status by the time of the index date in the case (i.e., symptom onset or first healthcare
contact), individual anonymized vaccination records were obtained from the Clinical Practice
Research Datalink (CPRD) [13]. This contains patient-level information for over 1,500 GP prac-
tices in the UK, including dates of Pandemrix doses given to children aged 6 months to 19 years
for both the 2009/10 and 2010/11 seasons as well as data on clinical risk group. CPRD data for
England were used to derive cumulative Pandemrix vaccine coverage figures stratified by calen-
dar day, age (6–11 months and then individual yearly age groups to 19 years as at January 2010)
and whether in a clinical risk group targeted to receive the influenza vaccine (S2 Fig). Narco-
lepsy cases were similarly allocated to a risk group based on the information provided by the GP
on clinical conditions considered high risk for influenza as of 2009.
Fig 1. Flow diagram for identification of study participants. HES, Hospital episode statistics; IT, information technology; MSLT, multiple sleep latency test.
https://doi.org/10.1371/journal.pmed.1003225.g001
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The association was calculated as the odds ratio (OR) for vaccination in the cases compared
with the matched population. This was done with logistic regression with the outcome as vacci-
nated (yes/no) in the cases and with an offset for the log odds of the matched coverage. As the
outcome is rare, ORs approximate to relative risks. The primary analysis used the first symptom
date as the index date with the symptom onset date from October 2009 to the date diagnosed by
the sleep center visit date. This primary analysis was based on ever receiving Pandemrix. and
was stratified by age group into<5, 5–19 years and by onset interval (<12 months, 12–23
months, 2–3 years, and 4–8 years after vaccination). All analyses were conducted as specified in
the preplanned analysis (S1 Text) with an additional post-hoc analysis in which the risk in the
first 2 years post-vaccination was further split into within 12 months and 12–23 months, and a
figure splitting the first 12 months into 0–5 and 6–11 months was generated. Sensitivity analyses
were carried out adjusting the vaccine coverage estimates by a relative ±20%; no risk group
adjustment; using earliest and latest symptom onset dates; excluding unvaccinated cases in
which the GP may have been unable to verify their status; and using first healthcare contact date
for which risk was assessed within 24 months, 2–3 years, or 4–8 years after vaccination.
A statistically significant elevated or reduced risk (p< 0.05) was inferred if the 95% confi-
dence intervals (CIs) for the OR did not contain 1. Analyses were conducted in Stata (Stata-
Corp. 2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP: https://
www.stata.com/).
Ethics approval
Public Health England is able to process identifiable data under Regulation 3 of The Health
Service (Control of Patient Information) (Secretary of State for Health, 2002). This is for pur-
poses related to communicable diseases and other risks to public health and includes the deliv-




Case notes for 811 potential narcolepsy patients were identified at the 3 centers. This included
140 patients reviewed as part of the previous study of which 93 were not eligible for this study
as they had onset before 2009. The case notes for the remaining 718 patients were reviewed
(Fig 1); of these, 440 had their first symptoms of narcolepsy before January 2009 or did not
have narcolepsy, and 21 did not have enough information available to assess the diagnosis.
These 461 patients were excluded. Of the remaining 257 cases, 237 were considered definite
narcolepsy, and for 20, anonymized case notes were sent to the expert panel for review. The
panel could confirm a diagnosis of narcolepsy for 7 of these cases, giving a total of 244 of
which 204 were categorized as type 1 narcolepsy and 40 as type 2 narcolepsy.
Vaccination history
The GP questionnaire was returned for 242 of the 244 patients; the remaining 2 patients were
excluded from further analyses. Pandemrix vaccine and date were reported for 44 patients
with a confirmatory batch number provided for 37. Of the 44 Pandemrix recipients, 39 were
vaccinated before and 5 after symptom onset. Two patients had received 2 doses, and for these,
the date of the last dose was used in the analysis as symptom onset occurred after the second
dose. There were 17 individuals reported as unvaccinated where the GP indicated that they
were not registered in their practice in 2009 and that record transfer did not occur, and a further
PLOS MEDICINE Narcolepsy in English children after Pandemrix
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23 reported as unvaccinated for whom date of registration at the practice was not provided. These
40 cases were retained for the primary analysis and counted as unvaccinated on the assumption
that an individual who did receive the vaccine and then developed narcolepsy would have ensured
this information was transferred when registering with a new GP. Of the 26 patients reported to
be in a risk group eligible for Pandemrix in 2009, 13 received the vaccine.
The demographic and clinical details of the 242 cases are shown in Table 1 by vaccination
status. Only 5 (2%) were under 5 years of age at the time of diagnosis. All cases with Type 1
narcolepsy also had cataplexy. Of the 39 cases with onset after vaccination, 36 (92%) had type 1
narcolepsy compared with 168 (82%) of those unvaccinated or vaccinated after onset. Of the
111 (46%) tested for human leucocyte antigen (HLA) DQB1 �06:02, all were positive. Fig 2A
shows the symptom onset date in the 242 cases, indicating the 39 who received Pandemrix
before onset. The decline in the number of narcolepsy cases with time in Fig 2A is consistent
with the lag time between onset and diagnosis; when plotted by diagnosis date (Fig 2B), the
cases show an even distribution over time.
Assessment of time to diagnosis by vaccination status
A total of 29 vaccinated and 101 unvaccinated cases with onset from January 2009 to Septem-
ber 2012 with at least 5 years of time in the study were included in this assessment. There was
some evidence of a shorter interval from the onset of symptoms to the patients’ first healthcare









Age at September 2009 (years) <5 53 24 2 79
5–11 109 12 2 123
12–19 36 3 1 40
Age at onset (years) <5 13 7 2 22
5–11 115 26 1 142
12–19 70 6 2 78
Age at diagnosis (years) 4 4 1 0 5
5–11 86 29 3 118
12–19 108 9 2 119
Sleep Center (date visited) Oxford (June 2018) 53 15 0 68
Papworth (Jan 2018) 25 2 1 28
St Thomas’ (Sep 2017) 120 22 4 146
Gender Male 103 24 1 128
Female 95 15 4 114
Risk group for influenza vaccine
in 2009
Yes 13 10 3 26
No 138 21 2 161
Not known 47 8 0 55
Diagnostic Category Type I 163 36 4 203
Type II 35 3 1 39
HLA DQB1�06:02 Positive 88 23 0 111
Not reported 110 16 5 131
CSF measurement Indicative of narcolepsy (�110
pg/ml)
11 10 1 22
Not reported 187 29 4 220
CSF, cerebrospinal fluid; HLA, human leucocyte antigen.
https://doi.org/10.1371/journal.pmed.1003225.t001
PLOS MEDICINE Narcolepsy in English children after Pandemrix
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003225 September 14, 2020 7 / 17
contact in the vaccinated cases (Fig 3A) although no difference in the interval from their first
healthcare contact to their diagnosis (Fig 3B). As a result, there was a shorter overall interval
from onset to diagnosis in vaccinated cases (Fig 3C), the median interval being 1.49 years for a
vaccinated case compared with 2.19 years for an unvaccinated case (p = 0.024).
Case-coverage analysis
Table 2 shows the results using date of symptom onset stratified by age group and interval to
symptom onset. There were 200 cases eligible for this analysis after excluding 3 cases for
whom only a latest onset date could be allocated, 26 whose onset was before the vaccine was
available in mid-October 2009 and 13 who were aged<6 months on January 1, 2010, and were
not eligible for vaccine that year.
Fig 2. Timing of onset (A) or diagnosis (B) for the 242 narcolepsy cases by vaccination status and monthly vaccine
uptake in the age-matched population.
https://doi.org/10.1371/journal.pmed.1003225.g002
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The OR of vaccination at any time before onset in those with narcolepsy compared with the
matched population by the same index date, was significantly elevated both in those who
received the vaccine before 5 years of age and those vaccinated when aged 5–19 years, with
similar ORs for the 2 age groups. In both, the period of elevated risk was confined to onsets
within 12 months of vaccination. Within the first 12 months the risk was highest in those with
onset within 6 months of vaccination (Fig 4).
There was no evidence of a reduced risk in any time period after 12 months. In the sensitiv-
ity analyses (Table 3) not matching on risk group gave similar results with an OR of 7.15 (95%
CI 3.89–13.14) for onsets within 12 months compared with 6.65 (95% CI 3.44–12.85) with risk
group matching (Table 2). Exclusion of the 17 patients reported to be unvaccinated but with-
out transferred GP records and the 23 whose registration status in 2009 was unknown
increased ORs as expected. Using the earliest possible symptom onset date reduced the effect
(OR for onset within 12 months 3.30 [95% CI 1.61–6.74]) and using the latest date increased
the effect (OR 8.33 [95% CI 4.36–15.91]) as some patients changed vaccination status. The
results were broadly similar to those in the main analysis when population vaccine coverage
was varied by a relative ±20% (e.g., 25% coverage observed in CPRD increased to 30% or
reduced to 20%). Analyses using date of first healthcare contact showed an elevated risk within
2 years, consistent with the delay between onset and initial consultation.
Attributable risk
The calculation for the vaccine-attributable risk is based on the OR for cases with onset within
12 months of vaccination and with adjustment for risk group status (6.65 as shown in Table 2).
Fig 3. Interval from symptom onset to first hcc (A), from first hcc to diagnosis (B) and from symptom onset to
diagnosis (C). In cases with onset from January 2009 to September 2012 and with at least 5 years of follow-up time.
hcc, healthcare contact.
https://doi.org/10.1371/journal.pmed.1003225.g003













<5 years Any time 24 63 0.266 1.77 (1.04–3.00)
<12 months 8 23 0.122 6.76 (2.10–21.72)
12–23 months 3 28 0.098 1.13 (0.30–4.33)
2–3 years 9 30 0.227 1.53 (0.66–3.54)
4–8 years 4 17 0.256 0.88 (0.28–2.83)
5–19 years Any time 15 137 0.060 2.18 (1.20–3.97)
<12 months 10 83 0.033 6.60 (2.97–14.68)
12–23 months 3 62 0.041 1.24 (0.35–4.42)
2–3 years 1 49 0.049 0.37 (0.05–2.85)
4–8 years 1 23 0.028 1.58 (0.21–11.83)
All ages Any time 39 200 0.125 1.94 (1.30–2.89)
<12 months 18 106 0.052 6.65 (3.44–12.85)
12–23 months 6 90 0.058 1.19 (0.47–2.99)
2–3 years 10 79 0.117 1.12 (0.54–2.34)
4–8 years 5 40 0.125 1.00 (0.36–2.80)
aCoverage in population by index date in case matched for risk group status and age at September 2009.
CI, confidence interval.
https://doi.org/10.1371/journal.pmed.1003225.t002
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Using the OR to approximate relative risk (RR), the attributable fraction ([RR−1]/RR) is 5.65/
6.65 (85.0%), which, from the total of 18 cases with onset within 12 months (Table 2), gives
15.3 vaccine-attributable cases.
To estimate the size of the catchment population of the 3 study centers, we identified the
number of children in England aged�19 years with a diagnosis of narcolepsy (ICD10 code
G47.4) in HES for the period January 1, 2008, to March 31, 2017 (n = 646). The number from
HES in the 3 centers for the same period was 263. Thus, we estimated that the 3 study centers
receive referrals from 263/646 (41%) of the pediatric population in England. The number of
doses received by the population covered by these 3 sleep centers was estimated from the
CPRD uptake in each age group × 0.41 × population in each age group in England (Office for
National Statistics population [14]), which gave a total of 528,001 doses (S1 Data). The attrib-
utable risk is therefore 15.3/528,001 = 2.9 per 100,000 doses or 1 per 34,500 doses.
Discussion
This study conducted 8 years after Pandemrix was first used in England allowed the risk of
narcolepsy to be re-evaluated by the inclusion of cases in whom the diagnosis occurred after
July 2011, the date at which follow-up was censored in the earlier study [5]. It confirmed an
elevated risk after Pandemrix, which was confined to those with onset within the first 12
months with a return to baseline thereafter. We found no evidence of a compensatory drop in
risk to below 1 after 12 months as might be expected if the vaccine had triggered onsets in
cases destined to occur later. Our study also showed that children who received the vaccine
under 5 years of age were at a similar increased risk to those vaccinated when older.
The 8-fold increased risk as measured by the OR for cases with onset within 6 months after
vaccination (Fig 4) was lower than that in our earlier study in which a 16-fold increased risk
was found for the same onset interval [5]. Because all the eligible cases at the 3 centers from the
Fig 4. Odds ratio of vaccination in narcolepsy cases compared with age-matched population prior to symptom onset according to time interval of onset since
vaccination.
https://doi.org/10.1371/journal.pmed.1003225.g004
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Total patients eligible for vaccination in





Not matching on risk group Any time 39 200 0.114 2.12 (1.44–
3.13)
<12 months 18 106 0.043 7.15 (3.89–
13.14)
12–23 months 6 90 0.051 1.35 (0.55–
3.34)
2–3 years 10 79 0.105 1.29 (0.62–
2.66)
4–8 years 5 40 0.131 0.94 (0.35–
2.58)
Dropping those without data transfer at GP
or not known if registered
Any time 39 172 0.124 2.54 (1.67–
3.86)
<12 months 18 93 0.051 8.74 (4.48–
17.05)
12–23 months 6 77 0.058 1.47 (0.57–
3.82)
2–3 years 10 66 0.115 1.48 (0.69–
3.19)
4–8 years 5 33 0.135 1.18 (0.41–
3.40)
Using earliest onset date as index date Any time 33 188 0.124 1.65 (1.08–
2.53)
<12 months 13 105 0.055 3.30 (1.61–
6.74)
12–23 months 6 91 0.045 1.63 (0.64–
4.16)
2–3 years 10 74 0.124 1.13 (0.54–
2.36)
4–8 years 4 31 0.138 0.91 (0.29–
2.88)
Using latest onset date as index date Any time 41 215 0.122 1.94 (1.31–
2.87)
<12 months 19 109 0.049 8.33 (4.36–
15.91)
12–23 months 5 95 0.058 0.89 (0.33–
2.38)
2–3 years 12 95 0.098 1.43 (0.72–
2.85)
4–8 years 5 48 0.127 0.76 (0.28–
2.07)
Decreasing uptake by a relative 20% Any time 39 200 0.100 2.57 (1.73–
3.83)
<12 months 18 106 0.042 8.57 (4.46–
16.45)
12–23 months 6 90 0.047 1.57 (0.62–
3.93)
2–3 years 10 79 0.093 1.50 (0.72–
3.13)
4–8 years 5 40 0.100 1.34 (0.48–
3.75)
(Continued)
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earlier study were included in the current analysis, this suggests some bias toward preferential
ascertainment of vaccinated cases in our earlier study. Although the interval between first
healthcare contact and diagnosis was similar in vaccinated and unvaccinated cases, the former
had a shorter interval from onset to first healthcare contact (Fig 3), which, with the short fol-
low-up interval in the earlier study, would have biased upwards the risk estimates. This earlier
contact with healthcare may reflect more severe or abrupt onset in vaccinated cases or knowl-
edge of the putative association prompting earlier consultation, even though the first evidence
of heightened public interest in narcolepsy (as judged by Google searches in the UK) did not
occur until December 2011 [15]. Despite the lower ORs in the current study, the estimated
attributable risk (1 per 34,500 doses) was higher than estimated in the previous study (around
1 in 55,00 doses) because of the inclusion of a substantial number of vaccine-attributable cases
with a diagnosis after July 2011.
The strengths of our study lie in the exhaustive search for potential narcolepsy cases at the
participating study centers using multiple data sources; the long follow-up interval, allowing
the inclusion of cases with delayed diagnoses; the independent verification of vaccination his-
tories from GP records; and the use of internationally agreed diagnostic criteria with case
inclusion decided on case note review without knowledge of vaccination status. Furthermore,
our study was adequately powered to look at the risk in sequential time periods post-vaccina-
tion. The conclusions from the main analysis (Table 2) were essentially the same in the sensi-
tivity analysis (Table 3). Our study should therefore help dispel the concerns raised about the
extent to which ascertainment bias, recall bias, and bias by indication affected the results in the
earlier studies in Finland, Sweden, and the UK [8,9].
Our study has a number of limitations. Our case ascertainment was restricted to 3 large
pediatric centers in southern England, and although the cases at these centers had similar
demographic features to cases attending other sleep centers in England (S1 Fig), the patient
populations may have differed in other ways we were unable to measure. Also we were unable






Total patients eligible for vaccination in





Increasing uptake by a relative 20% Any time 39 200 0.150 1.51 (1.00–
2.25)
<12 months 18 106 0.062 5.37 (2.76–
10.44)
12–23 months 6 90 0.070 0.93 (0.37–
2.36)
2–3 years 10 79 0.140 0.86 (0.41–
1.81)
4–8 years 5 40 0.150 0.77 (0.27–
2.16)
Using first healthcare contact as the index
date
Any time 42 217 0.122 2.00 (1.36–
2.96)
<24 months 21 99 0.071 5.83 (3.12–
10.71)
2–3 years 11 107 0.083 1.35 (0.66–
2.77)
4–8 years 10 91 0.114 0.95 (0.46–
1.94)
CI, confidence interval; GP, general practitioner.
https://doi.org/10.1371/journal.pmed.1003225.t003
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risks so had to assume that the proportion of narcolepsy cases in England seen at these centers
reflected the proportion of the pediatric population in England in the catchment area of the
centers. There is the possibility that some onset dates reported in the clinical notes may have
been influenced by patients’ knowledge of their vaccination status, particularly those that pre-
sented after the association with Pandemrix started to attract public attention in December
2011 [5]. However, using the more objective date of first healthcare contact as supplied by
GPs, an excess risk was still apparent within 2 years and at any time after vaccination. Bias due
to earlier presentation of vaccinated cases up to 8 years after vaccination seems unlikely. Our
conclusion that Pandemrix did not accelerate onsets in cases that would otherwise have
occurred later was based on the ORs after 12 months being consistently close to one. However,
there were relatively few cases in these later periods, and a small reduction or elevation in risk
could not be excluded. Although a Swedish study found a small elevated risk of onset in the
second year after vaccination, this was based on only 19 cases and was conducted within 3
years of Pandemrix use so could not include those with late diagnoses [16].
The epidemiological evidence for a causal association between Pandemrix and development
of narcolepsy in children based on our findings, and those of earlier studies in European is
compelling [7,17]. However, the mechanism behind the association and whether it is exclusive
to Pandemrix remains unclear. A multicountry study of adjuvanted H1N1 pandemic vaccines
failed to find an increased risk in children after Arepanrix, a Canadian-manufactured AS03
vaccine similar to Pandemrix, or Focetria, an MF59-adjuvanted vaccine [18]. However, these
estimates were based on single studies in Ontario and Taiwan, respectively. An earlier study of
Arepanrix in Quebec reported a relative risk of 4.32 (95% CI 1.50–11.2) in a cohort analysis in
under 20-year-olds, though with a very low attributable risk of around 1 per million doses
[19]. Further studies are needed to confirm whether the association between narcolepsy and
pandemic H1N1 vaccines is confined to Pandemrix.
Various hypotheses about the potential pathogenic mechanism underlying the association
between Pandemrix and narcolepsy have been advanced with the evidence suggestive of an
autoimmune mechanism. [20,21]. It has also been suggested that H1N1 pandemic influenza
infection itself can cause narcolepsy based on an increase in reported cases in Beijing and Tai-
wan in the wake of the 2009 pandemic [22,23]. However, this has not been seen in other set-
tings. The recently advanced hypothesis that prior H1N1 infection is a necessary condition for
Pandemrix-induced narcolepsy (the so-called 2-hit hypothesis) is, at present, purely specula-
tive [24].
Adjuvanted vaccines were shown to have superior protective efficacy to unajuvanted vac-
cines in the 2009 pandemic [25]. The case for their use in a future pandemic is therefore
strong, particularly if caused by a strain with a high case-fatality rate or to which the popula-
tion is immunologically naive. An AS03-adjuvanted H5N1 vaccine has been licensed by the
Food and Drug Administration in the United States for use in their national stockpile [26],
although its licensure is restricted to adults for whom the risk of narcolepsy after Pandemrix is
lower than in children [7]. However, without a proper understanding of the mechanism
whereby Pandemrix can cause narcolepsy and the role, if any, of wild virus influenza infection,
it is currently difficult to assess whether there might be a risk from future pandemic vaccines
containing AS03 but with a different pandemic strain.
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